CTOs on the Move

The THOR Group

www.thorgroup.com

 
The THOR Group is a Manhattan Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.thorgroup.com
  • 3601 N Aviation Blvd Ste 3900
    Manhattan Beach, CA USA 90266
  • Phone: 877.727.1777

Executives

Name Title Contact Details

Similar Companies

Tris Pharma

Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.

Formycon

Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.

Pacificord

Pacificord is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anika Therapeutics

Anika is a biomedical joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. For nearly 30 years and 35 million procedures worldwide, Anika has been passionately advancing quality patient care by enabling people to continue doing what they love. Anika. Your life. In Motion.

Auron Therapeutics

Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.